Marcus Meinhardt received his Diploma in Biotechnology with a specialization in neuropharmacology from the University of Applied Sciences Mannheim, Germany. He then completed his PhD at the Central Institute of Mental Health Mannheim, Germany, focusing on the glutamatergic system in alcohol dependence and its implications in different rat models of alcohol dependence. For his Post-doc, Marcus gained experience in the pharmaceutical industry at AbbVie, Ludwigshafen, Germany in the neuroscience drug discovery and DMPK department. Marcus recently returned to the Central Institute of Mental Health to investigate the neurobiological basis of psychedelics on both a pre-clinical and clinical level within the Department of Molecular Neuroimaging and at the Institute of Psychopharmacology. His main research interests lie in the therapeutic potential as well as molecular mechanisms of psychoactive substances.